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Background: Cervical cancer is a leading cause of death from cancer among women in low-resource settings,
affecting women at a time of life when they are critical to social and economic stability. In addition, the economic
burden is important for policy formulation. The aim of this study is to estimate patient side cost and to determine
predictors of its variation for the treatment of cervical cancer.
Methods: Analytic cross sectional study involving 227 cervical cancer cases at Tikur Anbessa Hospital, Ethiopia was
conducted. Cost estimation was based on patients' perspective and using the prevalence-based model as a time
frame. Productivity losses were estimated from lost working days.
Results: The mean outpatient cost per patient for cervical cancer was $407.2 (Median = $206.9). Direct outpatient
cost (Mean = $334.2) takes the largest share compared with the indirect counterpart ($150). The outpatient cost for
half of the respondent falls in a range between $93.7 and $478. The mean inpatient cost for hospitalized patients
was $404.4. The average direct inpatient cost was $329 (74% medical costs and 26% non medical costs). The mean
value for total inpatient cost for half of the respondents was in the range of $133.5 and $493.9. For every additional
day of inpatient hospital stay, there is a daily incremental inpatient cost of $4.2.
Conclusion: As has been found in other studies, our findings revealed that cervical cancer creates an immense
financial burden on patients. Primary prevention measures, vaccination against HPV and screening, should be
initiated and expanded to reduce morbidity from cervical cancer and subsequent costs in both human lives and
money resources. Control of co-morbidity and complication should be emphasized during management of cervical
cancer patients. Capacitating regional hospitals and provision of low cost or fee exemption schemes should be
arranged and strengthened.
Keywords: Cost of illness, Cervical cancer, Ethiopia, Human papilloma virusBackground
Cervical cancer is a disease in which the cells of the cervix
become abnormal and start to grow uncontrollably, form-
ing tumors. It is considered a disease of early and late mid-
dle age. Isolated cases are found to occur among young
women, but incidence rates are seen to rise sharply from
age 35 years [1]. Cervical cancer is a leading cause of death
from cancer among women in low-resource settings,
affecting women at a time of life when they are critical to
social and economic stability [2].* Correspondence: alemayehu4all@gmail.com
School of Public Health, Addis Ababa University, P.O.Box 9086, Addis Ababa,
Ethiopia
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distribution, and reproduction in any mediumWorldwide estimates in 2010 indicate that every year
493,243 women are diagnosed with cervical cancer and
273,505 die from the disease. The prevalence of cervical
cancer in the developing world is 59.4 per 100,000 [3].
In Africa the estimates indicate that every year 78,897
women are diagnosed and 61,671 die from the disease
[4]. According to the WHO estimates, in Ethiopia 7,600
are diagnosed with cervical cancer and roughly 6,000
women die of the disease each year [5].
Although there is no national cancer registry in Ethiopia,
reports from a retrospective review of biopsy results have
shown that it is the most prevalent cancer among women.
For instance, among 243 cancer cases, cervical cancerntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tal tract cancers in Gondar, Northwest Ethiopia [6]. Similar
studies in Addis Ababa and Yirgalem Hospital (Southern
Ethiopia) have also shown that it accounted for 32% [7] and
25.8% [8] of female malignancies, respectively. A study done
on 2,111 women attending hospitals and clinics in Addis
Ababa has also reported the prevalence of invasive cancer
to be 15.6/1000 of the studied population [9].
With the magnitude outlined above, the economic bur-
den of cervical cancer is considerable and highlights the
need for treatment and prevention options for this condi-
tion. According to a review research in the United States,
annual direct medical costs associated with cervical cancer
range from 300 to 400 million USD. With a wide range
across studies for estimates of the annual direct medical
costs associated with carcinoma in-situ (CIN) which range
from 700 million USD to 2.3 billion USD [10]. In the
United States, although the direct costs of cervical cancer
are substantial, only 10% of all expenditures are due to
invasive disease; more than two thirds of the total cost
being attributable to screening and testing. Annual indi-
rect costs resulting from lost productivity and loss of ear-
nings due to premature death are also significant and are
estimated to be higher than the direct costs [11].
According to a population-based study in Spain, dur-
ing a four year period (1999–2002), the mean cost of
hospitalization due to cervical cancer and carcinoma in
situ is 3,098 Euro and 2,192 Euro respectively [12].
Another retrospective study done in Tunisia has shown
that the direct medical care cost of cervical cancer as
ranging from 431 to 4143 Euro [13].
In Ethiopia no study has been documented that calcu-
lated the cost of cervical cancer. As resources are very
limited and the cost of medical care is rising, it is critical
to have an understanding of the economic aspect of cer-
vical cancer in order to develop and implement sound
public health policies. Therefore, this is study was
designed to estimate costs of treatment and to deter-
mine predictors for variations in cost of cervical cancer.
Both direct cost and productivity costs to the patients
were investigated. The results of this study can be used
as a basis for a full cost-utility analysis of the prevention




The study was carried out in the Departments of
Gynecology/Obstetrics and Oncology/Radiotherapy of
Addis Ababa University Tikur Anbessa Specialized
Teaching Hospital. Tikur Anbessa Hospital is the only
central referral hospital and cancer treatment and diag-
nostic center in the country that provides services for
patients from all over the country. Women make upabout 73% of the total patients at the center, and cancer
of the cervix is the most common disease comprising
over one-third of all female patients treated. The
Gynecology/Obstetrics Department also provides surgi-
cal treatment and evaluation and screening of new and
referral cases of cervical cancer, among other services.
Study design
This study is a cross-sectional quantitative study using a
hospital based analytic design.
Study population and sampling methods
Histologicaly confirmed and clinically staged 227 cer-
vical cancer patients who were attending outpatient and
inpatient services at Tikur Anbessa Hospital (Gyn-OPD
(40), gynecology ward (23), oncology referral clinic
(117), and oncology ward (47)) within the specified
period of data collection time (December 2011) and who
had started treatment at least 3 months before the date
of data collection were included in the study. The con-
secutive sampling technique was used to select the study
subjects.
For each specified departments, participant cases were
sampled proportional to size of the sample had been
provided. Ethical approval was secured from the Re-
search and Ethics Committee of the School of Public
Health. Written informed consent was obtained from
each study participant.
The research instruments
Structured closed-ended and partially open ended ques-
tionnaires were used. The first draft questionnaires were
in English and then they were translated to Amharic and
then back translated to English to check for consistency.
The questionnaires incorporate: general socio-demographic
variables, direct cost (consultation cost, investigations cost,
medicine cost, travel cost, food on the way to clinic cost),
indirect cost (opportunity cost of lost working time)
and socioeconomic characteristic of households. A pre-
prepared checklist was used to collect clinical data from
patients’ records. Six female nurses who have previous data
collection experience were deployed after two days of trai-
ning. Two data collection supervisors were assigned. The
questionnaires were administered using face to face inter-
view. Review of patient records was also done by the data
collector that interviewed the respective study participant.
Pre-test of the data collection instruments was done in
another hospital in Addis Ababa among 10 women
respondents.
Method of cost estimation
This cost of illness study was conducted from the per-
spectives of the patients. Micro-costing and bottom-up
approach was employed in order to estimate direct cost
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of productivity time losses. As a time frame, prevalence-
based model was used. Costs were calculated for each
patient for the 12 months preceding the day of interview.
The direct costs that were estimated include the direct
medical costs for laboratory, medication, and consult-
ation. Direct non-medical cost during outpatient visits
and hospital admissions were also included.
The indirect costs that were estimated were earnings
lost because of travel to outpatient visits/inpatients hos-
pital stay and those due to absences from work because
of illness related to cervical cancer. Time foregone in
seeking care and productive time lost was converted into
indirect cost based on the daily wage rate and then
multiplied by the number of working days lost. The daily
wage rate for monthly paid patients was estimated by
dividing their net monthly salary by 30 days. Daily wage
rate for daily paid patients were calculated based on the
women’s reported daily earnings. The indirect cost for
unemployed, students and women who were not able to
work due to physical or mental disability were not con-
sidered in the calculations [14].
Individual cost items were summed up to the categories
of medical costs, non-medical costs, and lost income. All
costs were measured in Ethiopian Birr and were converted
into US Dollar using the prevailing exchange rate during
the time of the study (1 US Dollar = Eth Birr 14.5). The
purchasing power parity (PPP) conversion factor for the
Ethiopian Birr during the data collection period was
0.3 [15].
Data analysis
The data were entered, cleared and analyzed using SPSS
Version 16 for Windows. Data analysis was performed
using scores, frequencies and percentages. A variety of
descriptive statistics such as mean, standard deviations,
medians and inter-quartile ranges were calculated.
Before proceeding to further analysis, the residuals and
the data had been examined for the fulfillment of the
following statistical assumptions: normality, sensitivity,
multicollinearity, and hetroscedasticity. Multiple linear
regressions using a forward stepwise selection proced-
ure, was employed to identify the predictors of cost vari-
ability. In the regression model, independent variables
with a P-value < 0.1 have been entered whereas only
statistically significant (P<0.05) variables were included
in the final model.
Results
Characteristics of the study participants
A total of 227 study participants were interviewed. The
mean (SD) age was 48.7 [12] years. The total numbers of
participants in the age range of 18–64 years were 204
(89.9%). More than half of the study participants weremarried (52.4%), illiterate (54.6%), and housewives (52%).
The majority (54.6%) of the respondents were from large
households of greater than 6 individuals. Monthly mean
household income was Birr 589 ($40.62) and the median
was Birr 500 ($34.48).
About a quarter (26.4%) of the respondents reside less
than 50 Km away from the Hospital. The rest (73.6%) of
the patients need to travel more than 100 km in order to
arrive at the Hospital from their place of residence.
Mean (SD) distance of the study participants’ residence
from the Hospital was 299.2 (239) km and the median
distance was 300 km. Sixteen (7.1%) of the patients came
from places that are more than 700 km away from the
Hospital.
As illustrated in Table 1, cervical cancer stage was
rated according to a staging scheme developed by the
International Federation of Gynecology and Obstetrics
[17]. Vast majority (46%) of the study participants were
diagnosed at stage II followed by stage III (40%). Only
15 (7%) were diagnosed in the first stage of the cancer.
Seventeen (7%) of the study participants were diagnosed
at stage IV (see Table 1).
Outpatient costs
Direct cost
Among a total of 227 participants, 207 (91.2%) have vi-
sited at least one of the providers at least once. The rest
20 (8.8%) came directly to the Tikur Anbessa Hospital.
Regarding the direct outpatient cost incurred at the
Tikur Anbessa Hospital (Table 2), mean cost for consult-
ation with a physician, investigations and medicines were
estimated to be Birr 33.2 ($2.29), Birr 401.0 ($27.65) and
Birr 568.7 ($39.22) respectively. From the total direct
cost, the cost of medicine represents the largest share
(48.4%), followed by investigations cost (34.1%).
Direct cost for non-medical reasons takes the lowest
share (14.7%) of the total cost. The mean cost for trans-
portation was Birr 81.6 ($5.63). Expenditures for other
items related with the illness (food, drink, bedroom, and
non-prescribed drugs) amounted to Birr 91.1 ($6.28),
which is 7.8% of the total direct cost.
The average outpatient direct cost per patient was Birr
7,060.1 ($486.91). The largest component was direct non-
medical cost (mean = 3,568.6 ($246.11) and median = 1,320
($91.03)). Mean expenses for non-prescribed remedies [Birr
2,816.6 ($194.25)] takes the largest share of non-medical
direct costs followed by expenses for food [Birr 527.3
($36.36)]. The mean cost of transportation fee was Birr
117.3 ($8.09).
The total direct medical cost for the 171 study partici-
pants was Birr 538,379 ($37129. 59). The average direct
medical cost was Birr 3,148.4 ($217.13) (median = 1,280
and SD = 5,140.1). The mean cost for physician consult-
ation, investigations and medicines came to Birr 111.29
Table 1 Socio-demographic and other characteristics of
the study subjects (*Birr 14.5=$1)
Characteristics n (%) Characteristics n (%)
Age Group Occupation
15-24 4 (1.8) House wife 118 (52.0)
25-34 21 (9.3) Farmer 45 (19.8)
35-44 48 (21.1) Government employee 13 (5.7)
45-54 75 (33.0) Merchant 13 (5.7)
55-64 58 (25.5) Private employed 12 (5.3)
64+ 21 (9.3) Daily laborer 8 (3.5)
Ethnicity Retired 6 (2.6)
Tigray 24 (10.6) Other 12 (5.2)
Amhara 104 (45.8) Family size
Oromo 64 (28.2) 1-2 22 (9.7)
Gurage 18 (7.9) 3-5 81 (35.7)
Others 17 (7.5) 6-8 24 (10.6)
Marital Status 9-11 70 (30.8)
Single 20 (8.8) 11+ 30 (13.2)
Married 119 (52.4) Monthly income in Birr*
Widowed 57 (25.1) 1 - 299 32 (17.9)
Separated 17 (7.5) 300 - 599 78 (43.6)
Divorced 14 (6.2) 600 - 899 35 (19.6)
Educational Status 900 - 1199 16 (8.9)
Illiterate 124 (54.6) 1200+ 18 (9.4)
Only read & write 44 (19.4) Distance from TAH in km
Grade 1-4 17 (7.5) <50 60 (26.4)
Grade 5-8 18 (7.9) 51-300 76 (33.5)
Grade 9-10/12 22 (9.7) 301-500 48 (21.1)
College & above 2 (0.9) 501-700 27 (11.9)
Religion 700+ 16 (7.1)
Orthodox 148 (65.0) Stage at diagnosis
Muslim 44 (19.0) Stage I 15 (7.6)
Protestant 31 (14.0) Stage II 104 (46.8)
Catholic 2 (1.0) Stage III 91 (40.1)
Other 2 (1.0) Stage IV 17 (7.5)
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(63%), respectively.
Indirect cost
On average, each of the cervical cancer cases had the ill-
ness for about nine months before first coming to the
Hospital. But great variation was seen among the cases
regarding the number of ill days with minimum of five
days up to eight years (mean (SD) = 269.4 (317.4) days).
The median duration of illness was 180 days. During the
time interval between the dates of onset of symptoms to
appearing at the Hospital, mean working days of 155.5were lost (with a median of 2 months). During this time,
the average loss of productivity amounted to Birr 1,228
($84.69).
The time for single trip to reach health services varies
from minimum of twelve minutes to maximum of ninety
six hours (with mean (SD) and median of 5.7 [9] and
3 hours respectively.
The median duration of stay as an outpatient for the
study participants was 180 days. In this duration, on aver-
age, the respondents had visited the Hospital outpatient
38 times. The mean loss of productivity was 119.4 working
days. Total lost earning (indirect cost) during this time




From the total of 227 study participants, 122 (53.7%)
were admitted and treated as inpatients in Tikur
Anbessa Hospital or somewhere else for at least a day.
Among the 122 hospitalized patients 98 (80%) had paid
directly for their treatments. The treatment cost of the
rest 20% was covered by other payers. The direct med-
ical cost for the hospitalized study participants was Birr
347,321 ($23953. 17) (Mean = Birr 3,544.1 ($ (244.42)
and Median = Birr 1,890 ($130.34)). The median cost for
drugs was Birr 800 ($55.17), that for consultation was
Birr 30 ($2.07), for investigation, it was Birr 500 ($34.48)
and for medical supplies, it was Birr 120 ($8.28) (n=32).
The total direct non-medical cost was Birr 121,408
($8372. 96) (Median = Birr 800 ($55.17)). The median
cost for non-prescribed remedies and for foods were Birr
300 ($20.69) and Birr 200 ($13.79) respectively
(see Table 4).
Indirect costs
With a total of 3.948 lost working days (Mean = 34 days,
Median = 16 days), the total forgone earnings borne by
the study participants because of cervical cancer due to
hospital stay was Birr 41,353 ($2851. 93) [Mean = 827
($57.03) and Median = 175 ($12.07)].
Predictors for variation in patient related cost
As provided in Table 5, the cost incurred by patients were
computed across two broad distinct categories; outpatient
(direct and indirect) and inpatient/ hospitalization (direct
and indirect) cost for those who were ever admitted due to
cervical cancer. To determine which socio-demographic/
economic and clinical characteristics influenced cost, a
multiple linear regression model was fitted to the cost data
for both outpatient and inpatient separately. The final
model includes seven variables, all of which were simultan-
eously significantly associated with outpatient cost of
cervical cancer (P < 0.05): residency distance from the
Table 2 Direct outpatient cost in Birr, Addis Ababa, Ethiopia 2011 (*Birr 14.5=$1)
Costs category Mean (%) Median SD (IQR)
Before first visiting Tikur Anbessa Hospital
Direct medical cost 1002.9 403 2021.6 (1030, 100)
Consultation Fee 33.2 (2.8) 20 47.6 (50, 25)
Investigations Fee 401 (34.1) 175 849.1 (500, 50)
Cost Of Drugs 568.7 (48.4) 100 1514.0 (450, 0)
Direct non-medical cost 172.8 30 1329.6 (115, 4)
Transportation Fee 81.6 (6.9) 25 147.8 (114, 3)
Cost for Other expenses 91.1 (7.8) - 1261.3 (0, 0)
Total direct cost 1175.7 475 2716.6 (1150, 150)
At Tikur Anbessa Hospital
Direct medical cost (n=171) 3148.4 1280 5140.1 (3530, 445)
Consultation Fee 111.2 (4) 30 596.9 (30, 5)
Investigations Fee* 1056.1 (34) 360 2357 (1000, 200)
Cost Of Drugs¥ 1981.1 (63) 600 3796.7 (2000, 150)
Direct non-medical cost 3568.6 1320 7828.2 (2995, 379)
Transportation Fee (n=215) 117.3 70 304.1 (120, 10)
Non-prescribed remedies (n=206) 2816.6 600 7614.4 (2000, 100)
For food (n=212) 527.3 200 1143.3 (550,70)
Total direct cost 7060.1 3425 10471.9 (7664, 1204)
* Investigations include laboratory tests ultrasound, pathologic examination, x-ray and any other diagnostic procedures.
¥ Drugs include all medication prescribed by the physician or any other medication taken in relation with the problems of cervical cancer.
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number of facilities visited, occupation (farmer), compan-
ion, source of energy (animal dug) and residency (out of
Addis Ababa).
Similarly, the prediction model for inpatient cost of
cervical cancer was developed. The final model included
three variables, all of which were simultaneously signifi-
cantly associated with inpatient cost of cervical cancer
(P < 0.05): duration of inpatient stay, co-morbidity and
current stage of cervical cancer (Stage II). According to
the model, longer duration of inpatient hospital stay and
existence of co-morbidity were associated with higherTable 3 Indirect outpatient costs in Birr; Addis Ababa, Ethiop
Costs category M
Before first visiting Tikur Anbessa Hospital
Duration of complaint in days (n=207) 2
Days remained out of work (n=185) 1
Time for transportation 5
Amount of wages lost in Birr (n=145) 1
At Tikur Anbessa Hospital
Duration of stay as outpatient in days (n=227) 3
Number of outpatient visits at TAH (n=220) 3
Days remained out of work in days (n=169) 1
Amount of wages lost in Birr (n=145) 1inpatient cost. Patients currently (at the time of inter-
view) at stage II incur additional Birr 4282.92 ($295.37)
compared with patients in other stages (see Table 6).
Discussion
This study, in addition to confirming the costliness of
cervical cancer as disclosed by other studies [17], has
produced some important key findings related to the
economics of cervical cancer that can be used as inputs
for further economic evaluation.
The large differences between mean and median










Table 4 Direct and indirect inpatient cost of cervical cancer in Birr; Addis Ababa, Ethiopia 2011 (*Birr 14.5=$1)
Cost category Mean Median SD (IQR)
Direct costs
Direct medical cost (n=98) 3544.1 1890 5331.5 (3361, 722)
Consultation 156.9 30 848.8 (50, 5)
Investigations 983.4 500 1650.5 (1000, 200)
Cost Of Drugs 2403.8 800 4231.3 (2500, 300)
Medical supplies (n= 32) 387.5 120 728.8 (500, 41)
Direct non-medical cost 1152,0 800 1312.0 (1593, 200)
Non prescribed remedies 676.6 300 1124.3 (962, 100)
For food 437.3 200 582.7 (600, 100)
Total (n=93) 4771.0 2802 6356.0 (5418, 1574)
Indirect costs
Duration of inpatient stay in days (n=122) 34.0 16 42.2 (41, 7)
Days remained out of work (n=95) 41.6 20 55.2 (90, 1)
Amount of wages lost (n=50) 827.0 175 1871.0 (500, 100)
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standard deviations presented in this study are large,
sometimes exceeding the means. Such a pattern is com-
monly observed when there is wide variation in treat-
ment patterns among patients, even amongst those
apparently exhibiting the same pattern of disease [18].
The mean age of the respondents was 48.7 years,
which is an early menopausal period. Most (54.6%) of
the respondents were illiterate followed by 23.2% of the
respondents that hadn’t attended any formal schooling
but can read and write. The vast majority (52%) were
housewives. These findings show that the poor, margina-
lized and uneducated segments of the population are
most affected by the disease. This may be useful infor-
mation for policy actions aimed at addressing issues of
inequity. These characteristics of the study participants
were also consistent with other studies conducted in
Ethiopia, and some other African and Latin American
countries [9,17,19-21].
The median duration of illness was 180 days. Number
of working days lost was also quite large (Median = 60
days). The delay may be due to low health seeking be-
havior, unawareness about available treatment options
and lack of access to transportation or financial pro-








Mean 4845.3 2173.7 5905.0
IQR (4824, 651) (3100,0) (6933, 1359)and mis-diagnosis due to lack of access to diagnostic
instruments and skilled professionals at the peripheral
health facilities may also be raised as reasons. Above all
the status of women in decision making at household level
may be one of the main contributing factors [22-26].
Any cost-of-illness study should always be viewed in
the context of potential limitations. Some of the costs
may be underestimated, some costs may be overesti-
mated and some costs may be totally omitted. This cost
of illness study is limited to the patient side cost, even
though it would be more comprehensive if it includes
other costs to the health system, health care provider,
the family and to society at large. Intangible costs (pain,
suffering, stigma and discrimination) were not also
included due to difficulties in measurement [14]. The
limitations of self-reported data must also be recognized
in interpreting the findings of this study.
The outpatient cost for almost half of the respondent
falls in a range between Birr 6,933 ($478) and Birr 1,359
($93.7). The mean inpatient cost for hospitalized patients
was Birr 5,863.2 ($404.4). The average direct inpatient cost
was Birr 4,771 ($329) (74% medical costs and 26% non-
medical costs). The mean value for total inpatient cost for
nearly half of the respondents were in a range of Birr









(5417, 1573) (500, 100) (7161, 1936)
Table 6 Multiple regression of variables on cost of cervical cancer; Addis Ababa, Ethiopia 2011 (*Birr 14.5=$1)
Unstandardized Beta (B) t p Adjusted R2
Outpatient cost 44.2%
(Constant) 3422.45 2.66 0.0095
Residency distance from TAH (Km) 9.7 3.12 0.0025
Number of employed household members 1434.26 3.88 0.0002
Number of Facility visited
0 ¼ otherwise





1 ¼ if Farmer
 7831.77 4.84 0.0001
Source of Energy
0 ¼ otherwise
1 ¼ Animal dug
 15452.69 3.03 0.0033
Companion
0 ¼ had companion
1 ¼ had no companion
 −4584.74 −3.03 0.0033
Residency
0 ¼ Addis Ababa
1 ¼ out of Addis Ababa
 −5805.61 −3.25 0.0017
Inpatient cost 46.6%
(Constant) −415.96 −0.34 0.7321




 4274.68 2.73 0.0092
Current stage
0 ¼ otherwise
1 ¼ Stage II
 4282.92 2.86 0.0066
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other studies done elsewhere it is quite clear that these
cost estimates were big enough to be huge economic bur-
den for the patients and their family members [13].
In terms of stages of illness, we found, the cost for
stage I was lower compared with stage II and stage III.
This finding was similar to findings from other study on
cervical cancer [18,27]. The cost for stage IV was less
compared with other lower stages. This could be due to
the reason that cases at stage one might be recovered
with minor procedures while other cases at other stages
demand intensive diagnostic and therapeutic procedures
as evidenced by the cervical cancer treatment protocol
recommended by FIGO [16]. It may also be due to li-
mited availability of treatment option for stage III and
stage IV cervical cancer in Ethiopia so that the patients
die quickly while a patient who has diagnosed at stage
two tried all treatment options available.
This study showed that distance of patients’ residence
from the Hospital, the number of employed household
members, number of facilities visited, occupation (farmer),
companion, source of energy used by patients household
(animal dug) and residency (out of Addis Ababa) were sig-
nificantly associated with costs. Some previous study
reported in line with this finding [28,29].
There is no previous study which estimates the cost of
cervical cancer in sub Saharan Africa. A comparison of
our findings with those of other cost of illness studies
of cervical cancer in other countries or other disease inEthiopia would be of limited value because of the diffe-
rence in the categories of cost, the methods, and the
pattern of health services utilization. This could be the
main weakness of any cost of illness study.Conclusion
Cervical cancer creates an immense economic bur-
den on patients and their families. The cost was
dependent on the distance of patients’ residence
from the hospital. Number of employed household
members, number of facilities visited and the
patient’s occupation was also a predictor of cost.
Longer duration of inpatient hospital stay and exist-
ence of co-morbidity were associated with higher in-
patient cost. Prevention of occurrence of cervical
cancer shall be the prime focus in order to ulti-
mately avoid the problem in all aspects including its
economic burden. Primary prevention measures,
vaccination against HPV and screening, should be
initiated and expanded to reduce morbidity from
cervical cancer and subsequent costs in both human
lives and money resources. Once cancer develops, it
needs to be controlled to avert the co-morbidities
and complications, which can again significantly in-
crease the cost of its management later. Capacitating
regional hospitals, and provision of subsidized or
exempted fee options for treatment and screening
should be initiated and strengthened.
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